News | Stroke | August 24, 2022

iHealthScreen Inc. Introduces An Automated Stroke Prediction Model, based on AI and Color Fundus Imaging

iHealthScreen is the First Company to Develop An AI- and Color-Fundus- Image-Based Stroke Prediction model, Funded by the National Institutes of Health (NIH) 

iHealthScreen is the First Company to Develop An AI- and Color-Fundus- Image-Based Stroke Prediction model, Funded by the National Institutes of Health (NIH) 


August 24, 2022 — iPredict late stroke prediction model provides a fully automated prediction score for incident stroke and identifies the individuals who are at risk of stroke within 5-years. These results were presented at the international conference: Society for Brain Mapping and Therapeutics World Congress and show that the prediction model may help prevent stroke, saving millions of people from death or disability. 

Once high-resolution images of the patient’s eyes have been captured using a color fundus camera and submitted to the iPredict AI System, the stroke prediction results are available in a fully automated report in less than 60 seconds. The entire test can easily and reliably be completed within 5 minutes. 

This prediction model offers an overall accuracy of 82.4% for identifying an individual at risk of having an incident stroke within 5-years. 

iPredict achieved higher accuracy than existing stroke prediction models such as Framingham and Chads scores (iPredict-stroke accuracy 82.4% compared to Framingham score 64.9%, and the CHADS2VASC score achieved 63.8% accuracy respectively on the same dataset). 

iPredict’s stroke model can be used to alert physicians of the need to take further preventive measures for these patients in the primary care setting. 

The company also has AI-based screening tools for early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma which are CE certified and TGA/Australian health approved. 

For more information: https://www.iHealthScreen.org 


Related Content

News | Heart Failure

November 30, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home November 30, 2023
Home
News | Heart Failure

November 30, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home November 30, 2023
Home
News | Heart Failure

November 16, 2023 — Mount Sinai’s Cardiovascular Research Institute is sending bioengineered human heart muscle cells ...

Home November 16, 2023
Home
News | Heart Failure

November 16, 2023 — A smartphone app using artificial intelligence technology to detect changes in the voice of a person ...

Home November 16, 2023
Home
News | Heart Failure

November 14, 2023 — Deepak Srivastava, MD, president of Gladstone Institutes and a renowned cardiovascular researcher ...

Home November 14, 2023
Home
News | Heart Failure

November 13, 2023 — Ultromics, a leading health technology company at the forefront of detection of heart failure and ...

Home November 13, 2023
Home
News | Heart Failure

November 3, 2023 — The national Board of Directors of the American Heart Association last week voted to provide full ...

Home November 03, 2023
Home
News | Heart Failure

October 20, 2023 — An international team of scientists has identified nearly a dozen genes that contribute to calcium ...

Home October 20, 2023
Home
News | Heart Failure

October 18, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Home October 18, 2023
Home
Subscribe Now